
Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia
The grant will enable leading international researchers to complete…

AMSilk Invited to Participate in VISION 2045 Summit
Leaders from across the world will convene at VISION 2045 Summit…

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Funds will be used to accelerate development of proprietary ambulant…

Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec
We were privileged to hear visionary insights during Mike Ward’s…

ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial
Los Angeles, California, USA, October 25th, 2022 – ImaginAb…

Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
alfapump achieves pre-specified primary effectiveness endpoints…

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor…

Gadeta Appoints Scientific Advisory Board and Provides Business Update
Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta…

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”),…

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase…

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
Targeting final lead therapy selection, neutralizing all known…

AMSilk Relocate Offices to Support Expansion Plans
The purpose-built offices will support its production of game-changing…

Neuraxpharm launches European campaign to increase awareness of medical cannabis
Neuraxpharm launches European campaign to increase awareness…

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V.…

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
Non-dilutive capital finances planned launch of ensifentrine…

ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia
Inglewood, California, October 17th 2022 – ImaginAb, Inc.,…

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona…

Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson’s Research Supports Development of Disease Modifying Therapy for Parkinson’s Disease
Copenhagen, Denmark and Boston, US, 11th October 2022 – Muna…

Novo Nordisk Foundation establishes fellowships with four top international universities
The Novo Nordisk Foundation is expanding and extending its Interdisciplinary…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York